Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data

Moderna and Merck delivered positive news about their personalized skin-cancer vaccine Wednesday. Investors bought their shares in droves.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。